Table 1.
Characteristics of CBD patients and controls
| Variable | CBD patients (N = 230) | Controls (N = 1312) |
|---|---|---|
| Age (years)1 | 70 (46, 96) | 69 (45, 92) |
| Sex | ||
| Female | 119 (51.7%) | 611 (46.6%) |
| Male | 111 (48.3%) | 701 (53.4%) |
| Age of CBD onset (years) | 64 (41, 86) | N/A |
| Disease duration (years) | 6 (2, 16) | N/A |
| Braak stage | ||
| 0 | 27 (13.8%) | N/A |
| I | 36 (18.4%) | N/A |
| II | 66 (33.7%) | N/A |
| III | 53 (27.0%) | N/A |
| IV | 11 (5.6%) | N/A |
| V | 2 (1.0%) | N/A |
| VI | 1 (0.5%) | N/A |
| Thal phase | ||
| 0 | 105 (53.6%) | N/A |
| 1 | 35 (17.9%) | N/A |
| 2 | 24 (12.2%) | N/A |
| 3 | 25 (12.8%) | N/A |
| 4 | 3 (1.5%) | N/A |
| 5 | 4 (2.0%) | N/A |
| CB overall tau pathology score | 0.77 (0.23, 1.75) | N/A |
| NFT overall tau pathology score | 2.19 (1.13, 2.62) | N/A |
| AP overall tau pathology score | 0.53 (0.24, 1.04) | N/A |
| NT overall tau pathology score | 2.52 (1.24, 2.95) | N/A |
CBD corticobasal degeneration, CB coiled bodies, NFT neurofibrillary tangles, AP astrocytic plaques, NT neuropil threads
The sample median (minimum, maximum) is given for age. 1 Age represents age at death in CBD patients and age at blood draw in controls. Information was unavailable in CBD cases for age of CBD onset (N = 42), disease duration (N = 42), Braak stage (N = 34), Thal phase (N = 34), CB overall tau pathology score (N = 34), NFT overall tau pathology score (N = 34), AP overall tau pathology score (N = 34), and NT overall tau pathology score (N = 34)